Dr. Chirag Jain's Mission: Transform How 20 Million Cancer Patients Worldwide Experience Pain – Join the Movement Mumbai, February 9, 2026 – Dr. Chirag Jain spent 18 years as a surgeon watching cancer destroy not just bodies, but souls. Today, he's building what could become the most significant transformation in oncology care since chemotherapy itself.

This isn't incremental improvement. This is a paradigm shift worth billions.

Mindful Gurukul Private Limited announced breakthrough clinical validation results and ₹4 crore investment from a US-based angel investor for Skitii – a patented AI music therapy platform that provides significant pain relief for cancer patients. But the real story? Dr. Jain is positioning this technology to reach every cancer treatment center on the planet.

The Billion-Dollar Opportunity: Transforming Oncology Care Globally, 20 million people are diagnosed with cancer annually. Each undergoes months of treatment. Each experiences debilitating pain and emotional trauma. The current solution? Opioids with devastating side effects, or nothing at all.

"We're not building a feature for cancer care – we're rebuilding the foundation of how oncology treats the whole patient," Dr. Jain declared. "This is a multi-billion dollar market that nobody has cracked because you need both deep clinical expertise AND cutting-edge AI innovation. We have both." The global pain management market is valued at $85 billion. Music therapy for healthcare? Barely explored at scale. AI-powered adaptive systems for cancer care? Dr. Jain's company is pioneering the category.

"This is the million-dollar idea – actually, the billion-dollar transformation," he said. "First mover advantage in a massive market where we're creating the category itself." The Surgeon Who Saw What Others Missed After 18+ years in surgery, Dr. Jain recognized what pharmaceutical companies and medical device giants overlooked: cancer patients don't just need drugs – they need emotional support that scales, that's available 24/7, that adapts to their individual suffering.

"As a surgeon, I could only be with patients for minutes. But their suffering lasted hours, days, months," Dr. Jain explained. "I realized the breakthrough wouldn't come from better surgery – it would come from technology that could provide compassionate presence when humans couldn't." So he stopped operating and started building the future of oncology care.

The Patented Technology That Changes Everything Skitii isn't just a music app. It's a medical device that uses proprietary patented algorithms to create personalized therapeutic music that adapts to each patient's unique physiological and emotional needs during cancer treatment.

The platform continuously monitors patients through advanced biometric sensing and responds dynamically when distress is detected – delivering precisely calibrated therapeutic interventions through sound.

Patented. Proven. Ready to Scale.

• Indian patents secured – international PCT applications filed for global protection • Clinical validation – significant pain reduction demonstrated in trials • US investor backing – ₹4 crore validates global market potential • DPIIT recognition – government-validated healthcare innovation • CDSCO approval in progress – Class B medical device regulatory pathway "This is patented technology being built in India to export to the world," Dr. Jain emphasized. "Under Prime Minister Modi's vision for healthcare self-reliance and innovation, Indian startups can dominate global healthcare markets. We're proving it." Why This Attracts Global Capital US-based seasoned Angel investor committed ₹4 crore because they see what Dr. Jain sees: a massive underserved market, proprietary patented technology, a founder who deeply understands the clinical problem, and a clear path to becoming the standard of care in oncology centers worldwide.

"International investors don't fund incremental improvements," Dr. Jain noted. "They fund transformation. They fund founders who can execute billion-dollar visions with defensible intellectual property. That's what we're building." Join the Transformation Dr. Jain is assembling a world-class team to execute this vision. Not just employees – co-creators of the future of cancer care.

Who Transforms Oncology with Dr. Jain: Innovators & Builders: "I need people who want to build technology that reaches 20 million patients, not 20,000 users" – Dr. Jain • AI/ML engineers passionate about healthcare applications • Medical device software architects • Algorithm developers with therapeutic technology experience • Full-stack developers who understand clinical workflows Clinical Visionaries: "Oncologists who understand we're not disrupting their work – we're multiplying their impact" – Dr. Jain • Forward-thinking hospital administrators • Cancer care centers ready to pioneer transformation • Clinicians who see beyond today's protocols Strategic Empire-Builders: • Medical device distributors for 50+ country expansion • Healthcare investors who fund category creation • Regulatory experts who navigate global approvals • Business development leaders who close hospital partnerships at scale Why Join a Surgeon-Founder Building a Billion-Dollar Vision? Dr. Jain brings what tech founders can't replicate: 18+ years of clinical credibility, hospital operations expertise, deep understanding of oncology workflows, and genuine patient empathy. Plus the founder's hunger to build something massive.

"I didn't leave surgery to build a small company," he said. "I left to transform how humanity treats cancer. That requires people who think bigger than anyone else in the room." The Traction Proving the Vision • Clinical impact: Patients reporting significant pain reduction and emotional relief • Regulatory momentum: CDSCO Class B approval pathway established • IP fortress: Indian patents secured + international PCT applications = defensible moat • Capital validation: ₹4 crore from sophisticated US investors • Market expansion: Clinical validation expanding, global pipeline building "This isn't a side feature oncologists might adopt," Dr. Jain explained. "This becomes as fundamental to cancer treatment as imaging or diagnostic testing. That's billion-dollar transformation." From India to Every Cancer Center on Earth This is India's moment. Not just consuming Western healthcare technology – exporting Indian innovation globally. A surgeon-founder building patented AI systems that solve problems Silicon Valley missed. International capital backing Indian execution.

"We're proving Indian startups can lead categories, not just participate," Dr. Jain said. "Cancer doesn't care about borders. Neither does our ambition." The Personal Mission Driving Billions "A patient undergoing chemotherapy told me the music felt like someone holding her hand," Dr. Jain shared. "That moment – when technology delivers humanity at scale – that's what drives me. Not the valuation. Not the market size. The knowledge that we're reducing suffering for millions of people who have no other option." The Invitation Dr. Jain is personally engaging with exceptional talent and visionary partners. This is the inflection point. Clinical validation advancing. Capital secured. Patents filed. Regulatory pathway clear. Market massive. Founder proven.

"If you want to work on incremental improvements, there are thousands of startups," Dr. Jain concluded. "If you want to transform a $85 billion market and actually change how humanity treats cancer with proprietary patented technology – reach out. Let's build this empire together." Contact Dr. Chirag Jain Directly: CEO & Co-founder, Mindful Gurukul Private Limited Email id : [email protected] Linkedin: https://www.linkedin.com/in/dr-chirag-jain/ About Dr. Chirag Jain & Mindful Gurukul Dr. Chirag Jain is a surgeon-turned-founder with 18+ years clinical experience, now leading the transformation of global oncology care. Mindful Gurukul Private Limited is a DPIIT-recognized, Mumbai-based healthcare technology startup building patented AI-powered therapeutic solutions for worldwide export. With secured Indian patents, international PCT applications, US angel investment backing, and clinical validation results, the company is positioned to become the standard of care in cancer treatment centers globally – serving 20 million+ patients annually and creating a billion-dollar category in adaptive AI therapeutics.

(Disclaimer: The above press release comes to you under an arrangement with NRDPL and PTI takes no editorial responsibility for the same.). PTI PWR